According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...

周一，H.C. Wainwright在Krystal Biotech（NASDAQ:KRYS）欧洲监管进程取得积极进展后，重申了对该公司的"买入"评级和221.00美元的目标价。根据 InvestingPro 数据，这家市值51.6亿美元的生物科技公司展现出令人印象深刻的财务指标。该公司保持着强劲的财务健康状况，整体评分为"优秀"，毛利率高达93%。Krystal ...

Krystal Biotech Inc (NASDAQ:KRYS) is set to release its Q4 2024 earnings on Feb 19, 2025. The consensus estimate for Q4 2024 ...

市值50亿美元、毛利率高达93%且根据InvestingPro评估财务状况"优秀"的生物科技公司Krystal Biotech Inc. (NASDAQ:KRYS)的首席会计官Kathryn Romano近期进行了一系列公司普通股交易。根据最新的SEC文件显示，Romano于2025年2月27日以每股175.22美元的价格出售了750股，总计131,415美元。该交易是按照预先制定的Rule 10 ...

Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $2,869.50 today based on a price of $178.29 for KRYS at the time of writing.

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...